Christopher J. Sweeney, MBBS

Christopher J. Sweeney, MBBS

Harvard University

Cambridge, MA

Christopher J. Sweeney, MBBS, is a Medical Oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, and Professor of Medicine at Harvard Medical School. He received his medical degree from the University of Adelaide in Australia, and then completed an internship at the Royal Adelaide Hospital. Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center in La Crosse, Wisconsin. He went on to complete a Fellowship in Hematology/Oncology at Indiana University Medical Center in Indianapolis, where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School in 2009. His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.

Disclosures:

Articles by Christopher J. Sweeney, MBBS

Overview of Treatment for Advanced Prostate Cancer, including Metastatic Disease – Novel Treatment

Christopher Sweeney, MD, MBBS, gives an overview of the most promising research into novel treatments for metastatic castration-resistant prostate cancer (mCRPC), focusing on phosphatidylinositol 3-kinase (PI3Kinase)/Akt inhibition, Poly ADP-ribose polymerase (PARP) inhibitors, and lutetium-labeled prostate-specific membrane antigen (Lu-PSMA). He emphasizes the importance of careful patient selection for these therapies, and suggests that future studies should focus on combination therapies and avoid duplicative research.

Read More

Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Christopher J. Sweeney, MBBS, gives an overview of the ENZAMET study, a companion to the ARCHES trial, the latter of which demonstrated a survival benefit in all versions of mHSPC (metastatic hormone-sensitive prostate cancer) with the use of enzalutamide. Dr. Sweeney discusses how ENZAMET builds on the research conducted with ARCHES, the differences between enzalutamide and chemotherapy for high-burden, rapidly progressing disease, and why monotherapy should be phased out for PCa treatment in most patients.

Read More

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Find Us:
375 Greenbrier Drive, Suite 100
Charlottesville, VA 22901

Call Us:
434-817-2000

Email Us:
Send Message

INFO

Privacy Policy
Terms & Conditions

Exercise & Wellness

Associate Editors


Mark A. Moyad, MD, MPH
University of Michigan
Ann Arbor, Michigan